Abstracts tagged "B-Cell Targets"

Abstract Number: 2573 • ACR Convergence 2025
Impaired Humoral Response to Recombinant Herpes Zoster Vaccine in Rituximab Treated Autoimmune Rheumatic Diseases Patients: A Prospective Controlled Phase 4 Study
Nadia Emi Aikawa¹, Henrique Dalmolin², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Emily Figueiredo Neves Yuki⁵, Carlos Emilio Insfran Echauri³, Clovis Artur Silva⁶ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Santa Casa de Sao Paulo and Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at increased risk for herpes zoster (HZ), especially those treated with B-cell depleting agents. Although the recombinant…
Abstract Number: 1837 • ACR Convergence 2025
Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus
John D. Mountz¹, Kathryn Sullivan², Shanrun Liu², Cynthia Liu², Min Gao², Walter Winn Chatham³, Tanecia Mitchell² and Hui-Chen Hsu², ¹University Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Systemic lupus erythematosus (SLE) is a predominantly female autoimmune disease, with a 9:1 female-to-male ratio. Our previous studies indicated that increased T-bet+ age-related B…
Abstract Number: 1172 • ACR Convergence 2025
A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease
Matthew Charles Baker¹, Audra Horomanski², Robert Fairchild³, Yuhan Liu³, Mariani Diaz Deluna³, Tobias Lanz⁴, Saurabh Gawde³, Mehdi Khalighi³, Benjamin Franc³, Mrudula Penta³, Nancy Pham³ and Kip Guja³, ¹Stanford University, Menlo Park, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴Stanford University, Stanford
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic, systemic, immune-mediated disease that is commonly treated with B cell depletion. However, due to potential risks associated with…
Abstract Number: 0903 • ACR Convergence 2025
Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
Catherine Wioland¹, Corinne Vedrine², Caroline Walter¹, Fanny Marque², Thomas Dannequin², Melanie Cecci¹, David Buffet¹, Cindy Schmid¹, Elena Degl'Innocenti¹, Gautier Robert¹, Grazyna Wieczorek¹, David Schubert¹, Catriona Paape¹ and Isabelle Isnardi³, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ³Novartis, Gueberschwihr, France
Background/Purpose: B cells are key players in the pathogenesis of Sjögren’s disease (SjD) and other systemic auto-immune diseases, supporting B cell depletion as an attractive…
Abstract Number: 0018 • ACR Convergence 2025
Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
Lin Huan, Hao Ran, Shiyi Wang, Xiaoping Zhang, Bing Yang, Yang He, Dandan Liu, Chenpeng Su, Chuan Chen, Xiaoqian Chen, Kezhen Ye, Liang Tian, Jian Peng and Zhenping Zhu, Helixon Therapeutics, New York
Background/Purpose: B cells and autoantibodies play a central role in the pathogenesis of various autoimmune diseases. Although CD19-targeted B cell depletion shows promising therapeutic potential,…
Abstract Number: 2488 • ACR Convergence 2025
Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
Kanako Chujo¹, Taichi Miyagi¹, Hiromi Shimada², Shusaku Nakashima², Yusuke Ushio¹, Koichi Sugihara², Mao Mizusaki², Naoto Manabe¹, Mayuko Wada², Risa Wakiya³ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Rituximab (RTX) was approved in Japan as a new treatment strategy for systemic sclerosis (SSc). Intravenous rituximab (375mg/m2) is administered once a week for…
Abstract Number: 1766 • ACR Convergence 2025
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
caterina ricordi¹, Maxime Beydon², Johanne Liberatore³, Pascal Cohen⁴, bertrand Dunogue⁵, Camille Mettler⁶, Benjamin Torreau⁷, Luc Mouthon⁵, Xavier Puéchal⁸ and Benjamin Terrier⁹, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Sorbonne University, INSERM, Institut Pierre Louis of Epidemiology and Public Health, Equipe PEPITES, Pitié Salpêtrière Hospital, Service of Public Health, Centre of Pharmacoepidemiology (Cephepi), Paris, France, ³Department of Internal Medicine, Centre Hospitalier d’Angouleme, Angouleme, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁶Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, Paris, France, ⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁹Cochin Hospital, Paris, France
Background/Purpose: Rituximab (RTX) is the standard of care for both induction and maintenance in ANCA-associated vasculitides (AAVs). While CD19 B-cell monitoring is used to evaluate…
Abstract Number: 1163 • ACR Convergence 2025
Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Lohr⁸, nicolas schleinitz⁹, Fernando Martinez-Valle¹⁰, Manu Nayar¹¹, Vinciane Rebours¹², Cory Perugino¹³, Kristen Clarkson¹⁴, Theresa Alexander¹⁴, Xinxin Dong¹⁴, Qian Huang¹⁴, Sue Cheng¹⁴ and Daniel Cimbora¹⁴, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Kansai Medical University Kori Hospital, Osaka, Japan, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Vall d’Hebron Hospital, Barcelona, Spain, ¹¹Freeman Hospital, Newcastle upon Tyne, United Kingdom, ¹²Beaujon Hospital, AP-HP, Université Paris-Cité, Clichy, France, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Amgen, Thousand Oaks, CA
Background/Purpose: IgG4-RD is a rare, chronic, fibroinflammatory disorder characterized by recurrent flares that can affect any organ and lead to permanent tissue damage. Inebilizumab (INEB)…
Abstract Number: 0897 • ACR Convergence 2025
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
william Galbavy, Hyunjin Kim, Brian Klotz, Marine Malbec, Carley Tasker, Eva Conde, Andrea Vecchione, Seblewongel Asrat, Benjamin Daniel, Weikeat Lim, Andre Limnander and Jamie Orengo, Regeneron, Tarrytown, NY
Background/Purpose: Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy (APECED) is a rare syndrome of multi-organ autoimmunity driven by the presence of self-reactive T cells and autoantibodies caused…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 2454 • ACR Convergence 2025
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Jonatan Tuncel¹, Trever Greene², Nicholas Brookhouser², Sandeep Kothapally Hanok¹, Seth Peng¹, Alison O’Conor¹, Parastoo Fazeli³, Jennifer Medlin⁴, Cara Bickers², Kelsea Hubka¹, Allison Aguilar¹, Wei Zhao¹, Kyla Omilusik¹, John Goulding¹, Tom Lee², Jode Goodridge², Marie Hu⁵, Veronika Bachanova⁵, Jeffrey Miller⁶, Matthew Lunning⁷, Rebecca Elstrom², Debra Zack¹, Vaneet Sandhu², Bahram Valamehr⁸ and Lilly Wong⁸, ¹Fate Therapeutics, San Diego, ²Fate Therapeutics, Inc., San Diego, ³UMN, ST PAUL, MN, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Minnesota, Minneapolis, ⁶University of Minnesota, Minneaspolis, MN, ⁷University of Nebraska Medical Center, Omaha, ⁸Fate Therapeutics, Inc., San Diego, CA
Background/Purpose: Autologous chimeric antigen receptor (CAR) T-cell therapy is an exciting new potential therapy for autoimmune diseases but limited in scope of application by logistical…
Abstract Number: 1761 • ACR Convergence 2025
The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
Juan Liang¹, Yinlian Zhang², Feng Li², Yingfeng Huang³, Ruixia Zhang³ and Ruixue Dai³, ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic), ³CytoCares, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by the production of autoantibodies targeting nuclear antigens, immune complex deposition, and chronic inflammation…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].